Co-Diagnostics (CODX) Stock Surges 9% Following Major South Asian Market Expansion

Key Highlights

Table of Contents

Co-Diagnostics (CODX) shares advanced 9.43% to reach $2.90 during Friday’s premarket session
CoSara Diagnostics, the company’s Indian joint venture, secured distribution rights for Bangladesh, Pakistan, Nepal, and Sri Lanka
The strategic expansion increases CoSara’s total addressable market across South Asia to approximately $13 billion
The initiative focuses on introducing the PCR Pro® point-of-care system and SARAGENE® product portfolio, subject to regulatory clearances
CoSara intends to hold a virtual distributor briefing during Q2 2026, followed by an in-person training summit later in the summer

Shares of Co-Diagnostics (CODX) jumped 9.43% to $2.90 during Friday’s premarket session following news of a significant territorial expansion by the company’s Indian joint venture.

Co-Diagnostics, Inc., CODX

CoSara Diagnostics Pvt. Ltd., a collaborative venture between Co-Dx and Ambalal Sarabhai Enterprises Limited (ASE Group), finalized an agreement to broaden its commercial footprint throughout South Asia. The expansion encompasses four additional territories: Bangladesh, Pakistan, Nepal, and Sri Lanka.

This strategic initiative elevates CoSara’s estimated addressable market within the region to approximately $13 billion, according to proprietary research and external market intelligence.

The territorial expansion aims to facilitate the market introduction of two primary offerings: the CoSara PCR Pro® point-of-care diagnostic system and the comprehensive SARAGENE® testing portfolio. Commercialization in each territory remains contingent upon obtaining necessary regulatory clearances.

CoSara has initiated efforts to build distribution infrastructure across all four newly acquired markets. This process involves navigating regulatory requirements, pinpointing strategic customer demographics, and forging partnerships with regional distribution networks.

Executive Perspectives on Regional Expansion

Mohal Sarabhai, CEO of CoSara, emphasized that South Asia demonstrates considerable and expanding demand for convenient, non-invasive molecular diagnostic solutions. He highlighted tuberculosis screening, HPV detection, and respiratory infection testing as critical application areas.

Dwight Egan, CEO of Co-Diagnostics, characterized the agreement as an extension of the company’s infrastructure-focused approach. The organization is prioritizing the development of regional manufacturing capabilities and distribution networks ahead of product launches—a blueprint being implemented across the United States, South Asia, and the Middle East and North Africa regions.

Egan indicated that this approach is intended to enable Co-Dx to achieve scalable worldwide deployment of its PCR point-of-care technology platform.

To facilitate distributor recruitment, CoSara has scheduled a virtual orientation session for Q2 2026. A comprehensive in-person distributor conference and training program will follow during the latter part of summer.

Current Stock Performance

CODX had been hovering near its 52-week bottom of $2.04 prior to Friday’s rally. The 9.43% premarket surge elevated the stock to $2.90.

Investors should note that the PCR Pro® system and associated platform products remain under FDA evaluation and are not currently authorized for commercial distribution.

In March, Co-Diagnostics also secured Japanese patent protection for its PCR platform innovations. Previously, the company successfully restored NASDAQ listing compliance following a brief period of uncertainty regarding its eligibility status.

The $13 billion total addressable market projection derives from company analysis and independent market research. Ultimate revenue realization will be determined by regulatory approval timelines and the velocity of distributor network development across the four expansion territories.

✨ Limited Time Offer